Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: A Randomized Trial

JAMA

Volumn 311, Issue 2, 2014, Pages 155-163

  Ebbert, Jon O ^a   Hatsukami, Dorothy K ^b   Croghan, Ivana T ^a   Schroeder, Darrell R ^a   Allen, Sharon S ^b   Hays, J Taylor ^a   Hurt, Richard D ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; DOPAMINE UPTAKE INHIBITOR; NICOTINIC AGENT; QUINOXALINE DERIVATIVE; VARENICLINE;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

ADULT; BENZAZEPINES; BUPROPION; DELAYED-ACTION PREPARATIONS; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84891959403     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.283185     Document Type: Article

References (26)

1. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341-350.
2. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56(9):395-401.
3. Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol. 2004;66(3):675-682.
4. Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006;34(1):121-130.
5. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474-3477.
6. Jorenby DE, Leischow SJ, NidesMA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685-691.
7. Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res. 2009;11(3):234-239.
8. Posner K. Suicidality issues in clinical trials: Columbia suicide adverse event identification in FDA safety analyses, 2007. http://www.fda.gov/ohrms/ dockets/ac/07/slides/2007-4306s1-01-CU-Posner.ppt. Accessed June 27, 2013.
9. Beck AT, Steer RA, Brown GK. Beck Depression Inventory Manual. 2nd ed. San Antonio, TX: Psychological Corp; 1996.
10. National Institutes of Health. NIH policy on reporting race and ethnicity data: subjects in clinical research, 2001. http://grants.nih.gov/grants/guide/ notice-files/NOT-OD-01-053.html. Accessed September 25, 2013.
11. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence. Br J Addict. 1991;86(9):1119-1127.
12. Croghan IT, Trautman JA, Winhusen T, et al. Tobacco dependence counseling in a randomized multisite clinical trial. Contemp Clin Trials. 2012;33(4):576-582.
13. Hughes JR. Minnesota Nicotine Withdrawal Scale - Revised. http://www.uvm.edu/~hbpl/?Page=minnesota/default.html. Accessed October 9, 2013.
14. Hughes JR, Keely JP, Niaura RS, et al. Measures of abstinence in clinical trials. Nicotine Tob Res. 2003;5(1):13-25.
15. Benowitz NL, Ahijevych K, Hall S, et al. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4(2):149-159.
16. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA. 2006;296(1):47-55.
17. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA. 2006;296(1):56-63.
18. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2012;1:CD006219.
19. Aubin HJ, Farley A, Lycett D, Lahmek P, Aveyard P.Weight gain in smokers after quitting cigarettes. BMJ. 2012;345:e4439.
20. Copeland AL, Martin PD, Geiselman PJ, Rash CJ, Kendzor DE. Smoking cessation for weight-concerned women. Addict Behav. 2006;31(1):115-127.
21. Pomerleau CS, Zucker AN, Stewart AJ. Characterizing concerns about post-cessation weight gain. Nicotine Tob Res. 2001;3(1):51-60.
22. Meyers AW, Klesges RC, Winders SE, et al. Are weight concerns predictive of smoking cessation? J Consult Clin Psychol. 1997;65(3):448-452.
23. Clark MM, Hurt RD, Croghan IT, et al. The prevalence of weight concerns in a smoking abstinence clinical trial. Addict Behav. 2006;31(7):1144-1152.
24. Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs. 2010;70(18):2357-2372.
25. Hughes JR. Effects of abstinence from tobacco. Nicotine Tob Res. 2007;9(3):329-339.
26. Foulds J, Stapleton J, HaywardM, et al. Transdermal nicotine patches with low-intensity support to aid smoking cessation in outpatients in a general hospital. Arch Fam Med. 1993;2(4):417-423.